Acne vulgaris: management

You can now review and comment on this draft guideline.

NICE is aware that the Medicines and Healthcare products Regulatory Agency (MHRA) is undertaking a review of isotretinoin.  When the findings of this review are available we will consider the impact on recommendations and update the guidance as necessary.

The consultation closes on Friday 5 February 2021, 5pm

How to comment

1. Register your organisation or comment as an individual

If you’re commenting for an organisation, your organisation needs to be registered as a stakeholder.

Not eligible? Contact the stakeholder organisation that most closely represents your interests and pass your comments to them.

We can accept comments from individuals. These will be considered, but you won’t get a formal response and they won’t be posted on the NICE website. Wherever possible we encourage you to submit your comments through a registered stakeholder organisation.

2. Read the consultation documents

Documents to comment on:

• Draft guideline– just the recommendations and their rationale
• Evidence reviews
  • Evidence review A - Information and support
  • Evidence review B - Skin care advice
  • Evidence review C - Diet
  • Evidence review D - Referral to specialist care
  • Evidence review E1 - Mild to moderate acne
  • Evidence review E2 - Mild to moderate pairwise analysis
  • Evidence review F1 - Moderate to severe acne
  • Evidence review F2 - Moderate to severe pairwise analysis
  • Evidence review G - Polycystic ovary syndrome
  • Evidence review H - Refractory acne
  • Evidence review I - Maintenance treatment
  • Evidence review J - Oral corticosteroids + oral isotretinoin
  • Evidence review K - Intralesional steroids
  • Evidence review L - Risk factors for scarring
  • Evidence review M - Management of scarring
• Supporting Documentation
  • Method
  • Supporting documentation - NGA team and collaborators from the TSU
  • Supporting documentation - TSU NMA software code (mild to moderate acne)
  • Supporting documentation - NMA data (mild to moderate acne)
  • Supporting documentation - NMA of efficacy included and excluded studies (mild to moderate acne)
  • Supporting documentation - NMA, direct and indirect estimates (mild to moderate acne)
  • Supporting documentation - TSU NMA software code (moderate to severe acne)
  • Supporting documentation - NMA data (moderate to severe acne)
• Economic model

If you want to review the economic model, please see 5. Economic models below and fill in the confidentiality form.

Other information about the consultation

• Equality impact assessment
• Committee membership list and DOI register
• Developing NICE guidelines: how to get involved

3. Add your comments

• You must use this comments form.
• You must declare any links with, or funding from, the tobacco industry

If you share similar views with another organisation, send a joint response.

Make sure you consider:

• The areas that will have the biggest impact on practice and be challenging to implement
• How to help users overcome challenges

Developing NICE guidelines: how to get involved suggests some other areas to comment on.

4. Email the form to us

Email: AcneManagement@nice.org.uk

Deadline: Friday 5 February 2021 at 5pm

5. Economic model

The developer has produced an economic model to support the guideline on Acne vulgaris: management. To receive an executable version of this model, please submit a request to AcneManagement@nice.org.uk with a signed copy of the confidentiality acknowledgement and undertaking form.

We will then send you a link to an executable version of the economic model by email. The deadline for returning your comments is the same as for the guideline consultation: Friday 5 February 2021